Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Liabilities: 2013-2025

Historic Total Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $889.5 million.

  • Amphastar Pharmaceuticals' Total Liabilities rose 8.80% to $889.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $889.5 million, marking a year-over-year increase of 8.80%. This contributed to the annual value of $845.2 million for FY2024, which is 3.24% down from last year.
  • Amphastar Pharmaceuticals' Total Liabilities amounted to $889.5 million in Q3 2025, which was up 3.69% from $857.9 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Total Liabilities ranged from a high of $949.5 million in Q3 2023 and a low of $194.8 million during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $857.9 million (2025), whereas its average is $800.2 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Total Liabilities skyrocketed by 328.61% in 2023 and then fell by 13.90% in 2024.
  • Amphastar Pharmaceuticals' Total Liabilities (Quarterly) stood at $226.0 million in 2021, then fell by 5.61% to $213.3 million in 2022, then surged by 309.46% to $873.5 million in 2023, then declined by 3.24% to $845.2 million in 2024, then climbed by 8.80% to $889.5 million in 2025.
  • Its Total Liabilities was $889.5 million in Q3 2025, compared to $857.9 million in Q2 2025 and $875.0 million in Q1 2025.